RECRUITING

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Talk to us

Conditions

Insulin ResistancePrediabetic StateOverweight and ObesityNon-Alcoholic Fatty Liver DiseaseHyperinsulinemiaHepatic steatosisDe novo lipogenesisGlucose production

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impact of single doses of both alpelisib and placebo (inert non-drug) in random order (like flipping a coin) in study participants. Participants will be asked to stay twice overnight in the hospital, take single doses of alpelisib and placebo (one or the other on each of the two hospital stays), and receive intravenous (into the vein) infusions of non-radioactive "tracer" molecules that allow researchers to measure the production of glucose (sugar) and fats by the liver. Measurements will be done both overnight, while participants are asleep and fasting (not eating or drinking other than water) and while consuming a standardized diet of nutritional beverages during the following day. The objective is to evaluate the effect of lowering insulin levels, while maintaining constant mild hyperglycemia, on plasma glucose and lipid levels.

Official Title

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Quick Facts

Study Start:2024-04-24
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06354088

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults aged 18-70 years, using highly effective contraception if of childbearing potential
  2. 2. Able to understand written and spoken English and/or Spanish
  3. 3. Body mass index of 18.0-39.9 kg/m2
  4. * For Group IS: BMI 18.0-29.9 kg/m2
  5. * For Group IR: BMI 25.0-39.9 kg/m2
  6. 4. Evidence of insulin sensitivity or insulin resistance:
  7. * Insulin sensitive (for Group IS) defined as all of the following: (1) Fasting serum insulin ≤ 12 µIU/mL, (2) Absence of dysglycemia (fasting plasma glucose \< 100 mg/dL and hemoglobin A1c \< 5.7%), and (3) Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score \< 2.5
  8. * Insulin resistant (for Group IR) defined as fasting serum insulin ≥ 15 µIU/mL plus at least one of the following: (1) Presence of prediabetic state (fasting plasma glucose 100-125 mg/dL and/or hemoglobin A1c 5.7-6.4%), and/or HOMA-IR ≥ 2.5
  1. 1. Inability to provide informed consent in English or Spanish
  2. 2. Concerns arising at screening visit:
  3. * Abnormal vital signs: (1) Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg and/or (2) Diastolic blood pressure \< 55 mm Hg or \> 100 mm Hg and/or (3) Abnormal resting heart rate \< 55 bpm (except at PI's discretion) or ≥ 110 bpm
  4. * Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant, including liver function abnormalities (either of the following): (1) Transaminases (AST or ALT) \> 3.0 x the upper limit of normal and/or (2) Total bilirubin \> 1.25 x the upper limit of normal
  5. * Laboratory evidence of diabetes mellitus: (1) Hemoglobin A1c ≥ 6.5%, and/or (2) Fasting plasma glucose ≥ 126 mg/dL
  6. 3. Reproductive concerns i. Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential ii. Women of childbearing potential not using highly effective contraception, defined as:
  7. * Surgical sterilization (e.g., bilateral tubal occlusion, bilateral oophorectomy and/or salpingectomy, hysterectomy)
  8. * Combined oral contraceptive pills taken daily, including during the study
  9. * Intrauterine device (levonorgestrel-eluting or copper) active at the time of the study
  10. * Medroxyprogesterone acetate (Depo-Provera®) injection active at the time of the study
  11. * Etonogestrel implants (e.g., Implanon®, etc.) active at the time of the study
  12. * Norelgestromin/ethinyl estradiol transdermal system (e.g., Ortho-Evra®) active at the time of the study iii. Women currently pregnant iv. Women currently breastfeeding
  13. 4. Concerns related to glucose metabolism
  14. * History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes)
  15. * History of gestational diabetes mellitus within the previous 5 years
  16. * Use of most antidiabetic medications (other than metformin) within the 90 days prior to screening: thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, amylin mimetics, acarbose, insulin iv. Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)
  17. 5. Concerns related to lipid metabolism
  18. * Known diagnoses of familial hypercholesterolemia, familial combined hyperlipidemia, or familial hyperchylomicronemia in the participant or a first-degree relative
  19. * Use of certain lipid-lowering drugs within 14 d prior to screening visit: fibrates (e.g., fenofibrate, gemfibrozil), prescription-strength omega-3 fatty acids (e.g., icosapent ethyl), high-dose niacin (\>100 mg daily)
  20. 6. Known, documented history, at the time of screening, of any of the following medical conditions:
  21. * Significant cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)
  22. * Severe liver disease, including advanced fibrosis and cirrhosis
  23. * Psychiatric diseases causing functional impairment that: (1) Are or have been decompensated within 1 year of screening, and/or (2) Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine)
  24. * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation
  25. * Bleeding disorders, including due to anticoagulation, or significant anemia (see above)
  26. * Active malignancy, or hormonally active benign neoplasm, except allowances for non-melanoma skin cancer and differentiated thyroid cancer (Stage I only)
  27. 7. Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above
  28. 8. Use of oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted
  29. 9. History of certain weight-loss (bariatric) surgery, including:
  30. * Roux-en-Y gastric bypass
  31. * Biliopancreatic diversion
  32. * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months
  33. 10. Clinical concern for alcohol overuse based on chart review and/or by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females
  34. 11. Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening
  35. 12. History of or ongoing febrile illness within 30 days of screening
  36. 13. Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data.
  37. 14. Known allergy/hypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
  38. 15. Dietary restrictions (e.g.., vegan, kosher, halal) on gelatin present in overencapsulation
  39. 16. Concurrent enrollment in another clinical study of any investigational drug/biologic therapy within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.
  40. * Prior participation in other studies led by Dr. Cook (PI) is excluded from this prohibition according to his medical/scientific judgment.

Contacts and Locations

Study Contact

Joshua R Cook, MD, PhD
CONTACT
2123056289
jrc2175@cumc.columbia.edu
Zachary D Sone
CONTACT
2123059336
zds2120@cumc.columbia.edu

Principal Investigator

Joshua R Cook, MD, PhD
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Columbia University Irving Medical Center
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Joshua R Cook, MD, PhD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-24
Study Completion Date2026-12

Study Record Updates

Study Start Date2024-04-24
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • Insulin resistance
  • Hyperinsulinemia
  • Non-Alcoholic Fatty Liver Disease
  • Hepatic steatosis
  • De novo lipogenesis
  • Glucose production

Additional Relevant MeSH Terms

  • Insulin Resistance
  • Prediabetic State
  • Overweight and Obesity
  • Non-Alcoholic Fatty Liver Disease